key: cord-0926492-z8w20js6
authors: van Damme, C.; Berlingin, E.; Saussez, S.; Accaputo, O.
title: Acute urticaria with pyrexia as the first manifestations of a COVID‐19 infection
date: 2020-04-24
journal: J Eur Acad Dermatol Venereol
DOI: 10.1111/jdv.16523
sha: 88f9ec841f4b34c3198893e3c13a9c906b0a1bb6
doc_id: 926492
cord_uid: z8w20js6

The coronavirus disease 2019 (COVID‐19) affects principally the respiratory tract but recent studies described that COVID‐19 could present a broader clinical spectrum from the absence of any symptoms to heart (1), digestive (2) or Ear‐Nose‐Throat (including anosmia and ageusia) (3) manifestations. Here we report two cases of peculiar skin manifestation.

Dear Editor,

The coronavirus disease 2019 (COVID-19) affects principally the respiratory tract but recent studies described that COVID-19 could present a broader clinical spectrum from the absence of any symptoms to heart 1 , digestive 2 or Ear-Nose-Throat (including anosmia and ageusia) 3 manifestations. Here we report two cases of peculiar skin manifestation.

A 71-year-old man was admitted to the hospital for general weakness, pyrexia and a cutaneous rash, all appearing the day before with strictly no other complaints. A dermatologist diagnosed a very extensive acute urticaria. There was no change in the patient's treatment or habits during the previous few weeks. He was allergic to iodine but no contrast agent had been injected before the eruption. His comorbidities included obesity (BMI 32), insulin-dependent diabetes mellitus, hypercholesterolemia, obstructive sleep apnea-hypopnea syndrome, high blood pressure, stroke 18 months ago without further sequelae, and kidney failure on dialysis 3 times a week. All his parameters, physical examination, two pairs of blood cultures, a PCR research of Influenza A and B on a nasopharyngeal smear and an electrocardiogram were normal. Blood test revealed a mild lymphopenia (1120/mm³), a slightly elevated CRP (13.2 mg/L > 5 mg/L) and increased liver enzymes (GOT, GPT, LDH, GGT doubled). Chest x-ray and abdominal CT-scan also failed to identify any infectious site. A few days after admission, the patient presented clinical deterioration with increased temperature and CRP, hypoxemia, unilateral ankle pain, constipation, chest pain, atrial fibrillation and tachycardia. A nasopharyngeal smear test revealed a COVID-19 infection. Urticaria improved gradually with bilastine. Unfortunately, he died 14 days after admission of end-stage respiratory failure following COVID-19 infection. Alongside that, some nephrologists, caregivers, and dialysis patients were tested positive. The pandemic hit Belgium in early February 2020 and the first case of COVID-19 was confirmed in our hospital on 9

March, when the patient's first symptoms started. Hygienic protective measures were not yet in place.

A 39-year-old nurse, who works in a rest home, went to the doctor for a generalized, pruritic urticarial rash (Fig. 1a,b) that had started two days ago on her forearms. Concomitantly, pyrexia (38.3°C) with chills, myalgia and headache had appeared. She also suffered from rhinorrhea, mild Accepted Article dry cough and dyspnea but had no digestive or urinary complaints. There was no change in her daily habits or drugs. She had been skiing three weeks earlier in Haute-Savoie, close to one of the cores of this pandemic. Bilastine gradually improved her rash. Anosmia and ageusia occurred five days after and lasted a week. Thereafter, her 8-year-old son developed an urticaria and her husband presented a radiologically confirmed COVID-19 infection.

Very few data are available concerning the association between urticaria and COVID-19. A medical team of Wuhan 4 has studied 140 patients infected with SARS-CoV-2, among whom they noticed two patients with chronic urticaria but did not mention any acute urticaria. More recently, an Italian report showed that, among 88 patients with confirmed diagnosis of COVID-19 who had not used any new medicine in the 15 previous days, 20.4% developed skin manifestations, including 3 widespread urticaria 5 . No correlation with the severity of the disease has been established until now. A recent survey of Belgian dermatologists 6 revealed an actual increasing incidence of (giant) urticaria and (urticarial) vasculitis. Chinese dermatologists 7 have observed these eruptions in COVID-19 pneumonia patients.

Based on these two case reports, we want to warn clinicians that urticaria with pyrexia in the current context of COVID-19 pandemic can be the first manifestations of this infection, even without any respiratory symptoms, like we observed for the anosmia 3 . These patients can unknowingly infect others and contribute to the spread of the COVID-19 infection, hence their necessary isolation. It is evident that urticaria can go with a viral infection and, due to the prevalence of COVID-19, we should consider this as a potential cause when doing our diagnosis.

Therefore we need to have rapidly more available screening tests to counter the underestimation of the number of cases. 

Potential Effects of Coronaviruses on the Cardiovascular System: A Review

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

Olfactory and Gustatory Dysfunctions as a Clinical Presentation of Mild to Moderate forms of the Coronavirus Disease (COVID-19): A Multicenter European Study

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China

Cutaneous manifestations in COVID-19: a first perspective

Dermatology staff participate in fight against Covid-19 in China